SCD and posterior cortical atrophy: Notably, when OA, the downstream product of SCD1, was supplemented in vitro, the anticancer effect of siSCD1 was significantly reduced, but PCa cells were still sensitive to combined CD36i alone and CD36i + siSCD1 therapy.